These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

575 related articles for article (PubMed ID: 29535126)

  • 41. Total DNA input is a crucial determinant of the sensitivity of plasma cell-free DNA EGFR mutation detection using droplet digital PCR.
    Zhang Y; Xu Y; Zhong W; Zhao J; Chen M; Zhang L; Li L; Wang M
    Oncotarget; 2017 Jan; 8(4):5861-5873. PubMed ID: 28052016
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Dynamics of Plasma EGFR T790M Mutation in Advanced NSCLC: A Multicenter Study.
    Yang Z; Li J; Hu Y; Chen M; Peng D; Zong D; Shang Q; Tao L; Zhao Y; Ni Y; Ye J; Xie Y; Yang L; Lin Q; Cai C; Xu N; Huang X; Dong X; Zhou Z; Yu Y; Shangguan Z; Xu Y; Ying W; Weng M; Yuan Z; Dong Z; Li J; Zheng Z; Pan J; Liu L; Ye J; Zhang Z; Li W; Zhu J; Jin S; Li Y; Ding C
    Target Oncol; 2019 Dec; 14(6):719-728. PubMed ID: 31691892
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Frequency of EGFR T790M mutation and multimutational profiles of rebiopsy samples from non-small cell lung cancer developing acquired resistance to EGFR tyrosine kinase inhibitors in Japanese patients.
    Ko R; Kenmotsu H; Serizawa M; Koh Y; Wakuda K; Ono A; Taira T; Naito T; Murakami H; Isaka M; Endo M; Nakajima T; Ohde Y; Yamamoto N; Takahashi K; Takahashi T
    BMC Cancer; 2016 Nov; 16(1):864. PubMed ID: 27821131
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Evaluation of the Idylla system to detect the EGFR
    Bocciarelli C; Cohen J; Pelletier R; Tran Van Nhieu J; Derman J; Favre L; Bourgogne A; Monnet I; Chouaid C; Pujals A
    Pathol Res Pract; 2020 Jan; 216(1):152773. PubMed ID: 31836323
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Highly sensitive and noninvasive detection of epidermal growth factor receptor T790M mutation in non-small cell lung cancer.
    He C; Zheng L; Xu Y; Liu M; Li Y; Xu J
    Clin Chim Acta; 2013 Oct; 425():119-24. PubMed ID: 23886554
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Exosome-based detection of activating and resistance
    Castellanos-Rizaldos E; Zhang X; Tadigotla VR; Grimm DG; Karlovich C; Raez LE; Skog JK
    Oncotarget; 2019 Apr; 10(30):2911-2920. PubMed ID: 31080561
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Highly sensitive detection of EGFR T790M mutation using colony hybridization predicts favorable prognosis of patients with lung cancer harboring activating EGFR mutation.
    Fujita Y; Suda K; Kimura H; Matsumoto K; Arao T; Nagai T; Saijo N; Yatabe Y; Mitsudomi T; Nishio K
    J Thorac Oncol; 2012 Nov; 7(11):1640-4. PubMed ID: 22899358
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Total and mutated EGFR quantification in cell-free DNA from non-small cell lung cancer patients detects tumor heterogeneity and presents prognostic value.
    Alegre E; Fusco JP; Restituto P; Salas-Benito D; Rodríguez-Ruiz ME; Andueza MP; Pajares MJ; Patiño-García A; Pio R; Lozano MD; Gúrpide A; Lopez-Picazo JM; Gil-Bazo I; Perez-Gracia JL; Gonzalez A
    Tumour Biol; 2016 Oct; 37(10):13687-13694. PubMed ID: 27473086
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Novel Selective and Potent EGFR Inhibitor that Overcomes T790M-Mediated Resistance in Non-Small Cell Lung Cancer.
    Li Y; Song Z; Jin Y; Tang Z; Kang J; Ma X
    Molecules; 2016 Nov; 21(11):. PubMed ID: 27827863
    [TBL] [Abstract][Full Text] [Related]  

  • 50. EGFR T790M Mutation in TKI-Naïve Clinical Samples: Frequency, Tissue Mosaicism, Predictive Value and Awareness on Artifacts.
    Lavdovskaia ED; Iyevleva AG; Sokolenko AP; Mitiushkina NV; Preobrazhenskaya EV; Tiurin VI; Ivantsov AO; Bizin IV; Stelmakh LV; Moiseyenko FV; Karaseva NA; Orlov SV; Moiseyenko VM; Korzhenevskaya MA; Zaitsev IA; Kozak AR; Chistyakov IV; Akopov AL; Volkov NM; Togo AV; Imyanitov EN
    Oncol Res Treat; 2018; 41(10):634-642. PubMed ID: 30145586
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients.
    Kuiper JL; Heideman DA; Thunnissen E; Paul MA; van Wijk AW; Postmus PE; Smit EF
    Lung Cancer; 2014 Jul; 85(1):19-24. PubMed ID: 24768581
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Brief Report on the Detection of the EGFR T790M Mutation in Exhaled Breath Condensate from Lung Cancer Patients.
    Smyth RJ; Toomey SM; Sartori A; O'Hanrahan E; Cuffe SD; Breathnach OS; Morgan RK; Hennessy BT
    J Thorac Oncol; 2018 Aug; 13(8):1213-1216. PubMed ID: 29751135
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A circulating tumor cell-based digital assay for the detection of EGFR T790M mutation in advanced non-small cell lung cancer.
    Wang J; Sun N; Lee YT; Ni Y; Koochekpour R; Zhu Y; Tseng HR; Wang S; Jiang L; Zhu H
    J Mater Chem B; 2020 Jul; 8(26):5636-5644. PubMed ID: 32525199
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Evidence-based best practices for
    Stockley T; Souza CA; Cheema PK; Melosky B; Kamel-Reid S; Tsao MS; Spatz A; Karsan A
    Curr Oncol; 2018 Apr; 25(2):163-169. PubMed ID: 29719432
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Exosome-based detection of EGFR T790M in plasma and pleural fluid of prospectively enrolled non-small cell lung cancer patients after first-line tyrosine kinase inhibitor therapy.
    Kim Y; Shin S; Lee KA
    Cancer Cell Int; 2021 Jan; 21(1):50. PubMed ID: 33435996
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Utility of Liquid Biopsy by Improved PNA-LNA PCR Clamp Method for Detecting EGFR Mutation at Initial Diagnosis of Non-Small-Cell Lung Cancer: Observational Study of 190 Consecutive Cases in Clinical Practice.
    Ito K; Suzuki Y; Saiki H; Sakaguchi T; Hayashi K; Nishii Y; Watanabe F; Hataji O
    Clin Lung Cancer; 2018 Mar; 19(2):181-190. PubMed ID: 29174086
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Detection of EGFR Mutations in Circulating Tumor DNA (ctDNA) Retrieved from Plasma - Interlaboratory Quality Assessment in the Czech Republic.
    Linda Č; Markéta K; Ivana T; Eva P; Milada M; Hana V; Ondřej H; Karolína B; Jiří D; Monika B; Pavel D
    Klin Onkol; 2018; 31(5):353-360. PubMed ID: 30541321
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A new sensitive and fast assay for the detection of EGFR mutations in liquid biopsies.
    Jensen SG; Epistolio S; Madsen CL; Kyneb MH; Riva A; Paganotti A; Barizzi J; Petersen RK; Børgesen M; Molinari F; Boldorini R; Lorenzen J; Sørensen E; Christensen UB; Høgdall E; Frattini M
    PLoS One; 2021; 16(6):e0253687. PubMed ID: 34166445
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The Dynamic Use of
    Macías M; Alegre E; Alkorta-Aranburu G; Patiño-García A; Mateos B; Andueza MP; Gúrpide A; Lopez-Picazo JM; Gil-Bazo I; Perez-Gracia JL; González Á
    Dis Markers; 2019; 2019():7954921. PubMed ID: 30809319
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A Randomized Phase II Study Comparing Nivolumab With Carboplatin-Pemetrexed for Patients With EGFR Mutation-Positive Nonsquamous Non-Small-Cell Lung Cancer Who Acquire Resistance to Tyrosine Kinase Inhibitors Not Due to a Secondary T790M Mutation: Rationale and Protocol Design for the WJOG8515L Study.
    Hayashi H; Chiba Y; Sakai K; Fujita T; Yoshioka H; Sakai D; Kitagawa C; Naito T; Takeda K; Okamoto I; Mitsudomi T; Kawakami Y; Nishio K; Nakamura S; Yamamoto N; Nakagawa K
    Clin Lung Cancer; 2017 Nov; 18(6):719-723. PubMed ID: 28623122
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.